198 related articles for article (PubMed ID: 38164565)
1. Diagnostic Performance of [
Ventura D; Dittmann M; Büther F; Schäfers M; Rahbar K; Hescheler D; Claesener M; Schindler P; Riemann B; Seifert R; Roll W
J Nucl Med; 2024 Feb; 65(2):192-198. PubMed ID: 38164565
[TBL] [Abstract][Full Text] [Related]
2. Incremental diagnostic value of [
Dittmann M; Gonzalez Carvalho JM; Rahbar K; Schäfers M; Claesener M; Riemann B; Seifert R
Eur J Nucl Med Mol Imaging; 2020 Oct; 47(11):2639-2646. PubMed ID: 32248325
[TBL] [Abstract][Full Text] [Related]
3. Role of
Piccardo A; Trimboli P; Puntoni M; Foppiani L; Treglia G; Naseri M; Bottoni GL; Massollo M; Sola S; Ferrarazzo G; Bruzzone M; Catrambone U; Arlandini A; Paone G; Ceriani L; Cabria M; Giovanella L
Thyroid; 2019 Apr; 29(4):549-556. PubMed ID: 30864903
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the usefulness of positron emission tomography with [18F]fluorodeoxylglucose performed to detect non-radioiodine avid recurrence and/or metastasis of differentiated thyroid cancer - a preliminary study.
Kolodziej M; Saracyn M; Lubas A; Brodowska-Kania D; Mazurek A; Dziuk M; Dymus J; Kaminski G
Nucl Med Rev Cent East Eur; 2021; 24(2):63-69. PubMed ID: 34382670
[TBL] [Abstract][Full Text] [Related]
5. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
6. The Diagnostic Value of
Bang JI; Park S; Kim K; Seo Y; Chong A; Hong CM; Choi M; Lee SW; Oh SW
Thyroid; 2023 Oct; 33(10):1224-1236. PubMed ID: 37597200
[No Abstract] [Full Text] [Related]
7. ¹⁸F-FDG PET/CT changes therapy management in high-risk DTC after first radioiodine therapy.
Rosenbaum-Krumme SJ; Görges R; Bockisch A; Binse I
Eur J Nucl Med Mol Imaging; 2012 Sep; 39(9):1373-80. PubMed ID: 22718304
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG SPECT/CT in the diagnosis of differentiated thyroid carcinoma with elevated thyroglobulin and negative iodine-131 scans.
Ma C; Wang X; Shao M; Zhao L; Jiawei X; Wu Z; Wang H
Q J Nucl Med Mol Imaging; 2015 Jun; 59(2):220-7. PubMed ID: 24844253
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT concurrent with first radioiodine post-therapeutic scan in high risk differentiated thyroid cancer: a useful tool or just an expensive diversion?
Rizzo A; Perotti G; Zagaria L; Lanni V; Racca M; Palestini N; Salvatori M
Q J Nucl Med Mol Imaging; 2023 Jun; 67(2):158-166. PubMed ID: 35238517
[TBL] [Abstract][Full Text] [Related]
10. Recurrent differentiated thyroid cancer: towards personalized treatment based on evaluation of tumor characteristics with PET (THYROPET Study): study protocol of a multicenter observational cohort study.
Kist JW; de Keizer B; Stokkel MP; Hoekstra OS; Vogel WV;
BMC Cancer; 2014 Jun; 14():405. PubMed ID: 24906384
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer.
Qiu ZL; Xue YL; Song HJ; Luo QY
Nucl Med Commun; 2012 Dec; 33(12):1232-42. PubMed ID: 23111353
[TBL] [Abstract][Full Text] [Related]
12. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
13.
Parihar AS; Mittal BR; Kumar R; Shukla J; Bhattacharya A
Thyroid; 2020 Apr; 30(4):557-567. PubMed ID: 31870227
[No Abstract] [Full Text] [Related]
14. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
15. Optimal threshold of stimulated serum thyroglobulin level for
Chai H; Zhang H; Yu YL; Gao YC
J Huazhong Univ Sci Technolog Med Sci; 2017 Jun; 37(3):429-432. PubMed ID: 28585147
[TBL] [Abstract][Full Text] [Related]
16. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Capabilities of MRI Versus 18F FDG PET-CT in Postoperative Patients with Thyroglobulin Positive, 131I-negative Local Recurrent or Metastatic Thyroid Cancer.
Samanci C; Onal Y; Sager S; Asa S; Ustabasioglu FE; Alis D; Akman C; Sonmezoglu K
Curr Med Imaging Rev; 2019; 15(10):956-964. PubMed ID: 32008523
[TBL] [Abstract][Full Text] [Related]
18. Initial Clinical Investigation of [18F]Tetrafluoroborate PET/CT in Comparison to [124I]Iodine PET/CT for Imaging Thyroid Cancer.
Samnick S; Al-Momani E; Schmid JS; Mottok A; Buck AK; Lapa C
Clin Nucl Med; 2018 Mar; 43(3):162-167. PubMed ID: 29356744
[TBL] [Abstract][Full Text] [Related]
19. PET/CT in the management of differentiated thyroid cancer.
Zampella E; Klain M; Pace L; Cuocolo A
Diagn Interv Imaging; 2021 Sep; 102(9):515-523. PubMed ID: 33926848
[TBL] [Abstract][Full Text] [Related]
20. Clinical role of 18F-FDG PET/CT for detection of radioactive iodine refractory differentiated thyroid cancer.
Tang X; Shi L; Zhao Z; Wang J; Yang R; Huang Y; Tang J; Chen Z; Wang F
Medicine (Baltimore); 2023 Jun; 102(24):e33878. PubMed ID: 37327310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
